Source link : https://newshealth.biz/health-news/targeted-combo-boosts-pfs-in-braf-mutant-metastatic-colorectal-cancer/
CHICAGO — Adding encorafenib (Braftovi) and cetuximab (Erbitux) to FOLFIRI chemotherapy significantly improved progression-free survival (PFS) as first-line treatment of BRAF V600E-mutated metastatic colorectal cancer, according to secondary analysis of a randomized trial. Results from cohort 3 of the BREAKWATER trial showed that adding the two targeted therapies to FOLFIRI (leucovorin, fluorouracil, and irinotecan) chemotherapy […]
The post Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-01 19:44:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8